Efficacy and safety of antiretroviral regimens including raltegravir to treat HIV-infected patients with hemophilia

Xiao, Hong; Xue, Ying; Shiming, Gu; Wang, Jiangrong; Sun, Hong-qing; Lu, Hongzhou

doi:10.5582/bst.2015.01180

Cited by 4 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is compelling evidence that variation in HIV-1 subtypes could influence the development of drug resistance and the susceptibility to certain antiretroviral drugs (17)(18). Certain integrase mutations do differ according to subtype in response to integrase inhibitor efficacy (19). From our analysis, however, there was no significant relationship of HIV-1 subtypes and occurrence of mutations.…”

Section: Discussioncontrasting

confidence: 63%

Characterization of HIV-1 Integrase Gene and Resistance Associated Mutations Prior to Roll out of Integrase Inhibitors by Kenyan National HIV-Treatment Program in Kenya

Mabeya¹,

Nyamache²,

Ngugi³

et al. 2020

Ethiop J Health Sci

View full text Add to dashboard Cite

BACKGROUND: Antiretroviral therapy containing an integrase strand transfer inhibitor plus two Nucleoside Reverse Transcriptase inhibitors has now been recommended for treatment of HIV-1-infected patients. This thus determined possible pre-existing integrase resistance associated mutations in the integrase gene prior to introduction of integrase inhibitors combination therapy in Kenya.METHODS: Drug experienced HIV patients were enrolled at Kisii Teaching and Referral in Kenya. Blood specimens from (33) patients were collected for direct sequencing of HIV-1 polintegrase genes. Drug resistance mutations were interpreted according to the Stanford algorithm and phylogenetically analysed using insilico tools.RESULTS: From pooled 188 Kenyan HIV integrase sequences that were analysed for drug resistance, no major mutations conferring resistance to integrase inhibitors were detected. However, polymorphic accessory mutations associated with reduced susceptibility of integrase inhibitors were observed in low frequency; M50I (12.2%), T97A (3.7%), S153YG, E92G (1.6%), G140S/A/C (1.1%) and E157Q (0.5%). Phylogenetic analysis (330 sequences revealed that HIV-1 subtype A1 accounted for majority of the infections, 26 (78.8%), followed by D, 5 (15.2%) and C, 2 (6%).CONCLUSION: The integrase inhibitors will be effective in Kenya where HIV-1 subtype A1 is still the most predominant. However, occurring polymorphisms may warrant further investigation among drug experienced individuals on dolutegravir combination or integrase inhibitor treatment.

show abstract

Section: Discussioncontrasting

confidence: 63%

Characterization of HIV-1 Integrase Gene and Resistance Associated Mutations Prior to Roll out of Integrase Inhibitors by Kenyan National HIV-Treatment Program in Kenya

Mabeya¹,

Nyamache²,

Ngugi³

et al. 2020

Ethiop J Health Sci

View full text Add to dashboard Cite

show abstract

“…Three INSTIs, RAL, EVG and DTG have been approved for clinical use by the FDA and European Medicines Agency [ 6 – 8 ]. These compounds have proven to be highly efficient for the treatment of both ARV-naïve and -experienced individuals even with preexisting drug resistance or treatment complication [ 9 – 15 ], thus INIs has rapidly became an important class in the arsenal of ARV drugs. Eighty HIV-1 untreated patients were recruited in this study in order to examine the variability within the IN gene at positions associated with resistance to INIs.…”

Section: Main Textmentioning

confidence: 99%

“…To date three INSTIs, raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG) are approved for clinical use [ 6 – 8 ]. They are potent ARV drugs offering more treatment options in naïve patients as well in pretreated patients with preexisting drug resistance or treatment complication [ 9 – 15 ]. Therefore, they have become an essential component of HAART used in many countries.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco

Alaoui

Touil

et al. 2018

BMC Res Notes

View full text Add to dashboard Cite

ObjectiveThe integrase strand-transfer inhibitors (INSTIs) are an important class in the arsenal of antiretroviral drugs designed to block the integration of HIV-1 cDNA into the host DNA through the inhibition of DNA strand transfer. In this study for the first time in Morocco, the complete HIV-1 integrase gene was analysed from newly diagnosed patients to evaluate the prevalence of natural polymorphisms and INSTIs resistance-associated mutations in the integrase gene.ResultsThe 864pb IN coding region was successfully sequenced from plasma sample for 77 among 80 antiretroviral naïve patients. The sequences were interpreted for drug resistance according to the Stanford algorithm. Sixty samples were HIV-1 subtype B (78%), fourteen CRF02_AG (18%), two subtype C and one subtype A. Overall 81 of 288 (28%) amino acid IN positions presented at least one polymorphism each. We found 18 (36.73%), 42 (25.76%) and 21 (27.27%) of polymorphic residues assigned to the N-Terminal Domain, Catalytic Core Domaine and the C-Terminal Domain positions respectively. Primary INSTIs resistance mutation were absent, however secondary mutations L74IM, T97A were detected in four samples (5.2%). These results demonstrate that untreated HIV-1 infected Moroccans will be susceptible to INSTIs.Electronic supplementary materialThe online version of this article (10.1186/s13104-018-3492-5) contains supplementary material, which is available to authorized users.

show abstract

Antiretrovirals

2017

Reactions Weekly

View full text Add to dashboard Cite

Efficacy and safety of antiretroviral regimens including raltegravir to treat HIV-infected patients with hemophilia

Cited by 4 publications

References 11 publications

Characterization of HIV-1 Integrase Gene and Resistance Associated Mutations Prior to Roll out of Integrase Inhibitors by Kenyan National HIV-Treatment Program in Kenya

Characterization of HIV-1 Integrase Gene and Resistance Associated Mutations Prior to Roll out of Integrase Inhibitors by Kenyan National HIV-Treatment Program in Kenya

Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco

Antiretrovirals

Contact Info

Product

Resources

About